First Commonwealth Financial Corp
Change company Symbol lookup
Select an option...
FCF First Commonwealth Financial Corp
PTOTF Patriot One Technologies Inc
GIM Templeton Global Income Fund
NSTC Northern Star Investment Corp III
WMLLF Wealth Minerals Ltd
NVVE Nuvve Holding Corp
ICCC ImmuCell Corp
MET MetLife Inc
FAST Fastenal Co
PFTA Portage Fintech Acquisition Corp
Go

Financials : Banks | Small Cap Value
Company profile

First Commonwealth Financial Corporation is a financial holding company for First Commonwealth Bank (the Bank). First Commonwealth Bank is a Pennsylvania bank and trust company. The Bank provides a diversified array of consumer and commercial banking services. It also provides trust and wealth management services and offers insurance products through the Bank and its other operating subsidiaries. The Bank operates approximately 118 community banking offices throughout western and central Pennsylvania, and northeastern, central and southwestern Ohio, as well as corporate banking centers in Pittsburgh, Pennsylvania, and Columbus, Canton and Cleveland, Ohio, and mortgage banking offices in Wexford, Pennsylvania, and Hudson, Westlake and Lewis Center, Ohio. The Bank also operates a network of approximately 136 automated teller machines (ATMs), at various branch offices and offsite locations.

Price
Delayed
$14.48
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.53
Day's Low
14.39
Volume
(Light)

Today's volume of 51,659 shares is on pace to be much lighter than FCF's 10-day average volume of 338,523 shares.

51,659

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

11:36 am ET October 4, 2022 (PR Newswire) Print

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ: KRBP) for violations of the federal securities laws.

https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on July 2, 2021 (the "IPO"), and/or between June 25, 2021 and August 13, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 4, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Kiromic received communications from the FDA on June 16 and 17, 2021, placing a clinical hold on its two candidate products. The Company failed to inform investors of this clinical hold despite the fact it learned of the hold before the IPO occurred. The Company's IPO offering documents stated that clinical testing would move forward in the third quarter of 2021. The Company did not proceed with this test due to the clinical hold. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Kiromic, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:The Schall Law FirmBrian Schall, Esq.,www.schallfirm.comOffice: 310-301-3335info@schallfirm.com

https://c212.net/c/img/favicon.png?sn=LA92387&sd=2022-10-04

View original content to download multimedia:https://www.prnewswire.com/news-releases/final-deadline-alert-the-schall-law-firm-encourages-investors-in-kiromic-biopharma-inc-with-losses-of-100-000-to-contact-the-firm-301640252.html

SOURCE The Schall Law Firm

https://rt.prnewswire.com/rt.gif?NewsItemId=LA92387&Transmission_Id=202210041136PR_NEWS_USPR_____LA92387&DateId=20221004

comtex tracking

COMTEX_415908157/1005/2022-10-04T11:36:09

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.